Penicillin

Penicillin

Penicillin is an anti-biotic agent used for the treatment of bacterial infections. It is derived from the mould of penicillium notatum. It works by disrupting the bacterial cell wall, leading to cell lysis. There are various types of penicillin and its derivates available, each one of which has specific action against specific bacteria. Due to this property of penicillin, it is used in the treatment of diseases such as throat infection, meningitis and other medical conditions.

The burgeoning demand for penicillin is attributed to an increase in the prevalence of infectious diseases globally. This is attributed to the high infectious risk of tuberculosis, respiratory diseases, skin diseases and other respiratory diseases. For instance, according to WHO 2023 report, In 2021, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide. Further as per the above-mentioned source approximately, six million men, 3.4 million women and 1.2 million children. Additionally, merger and acquisition activities are also driving the market growth for penicillin globally. For instance, in 2019, Ampliphi Biosciences C3J therapeutic merged to focus on the development of a phage-based therapeutic candidate for antibiotic resistance, this will infect the bacteria and kill it for antibiotic resistance. These above-mentioned elements are anticipated to fuel the growth of the market in the forecasted period.

• Based on type, the market is segmented into amino penicillin, beta-lactamase inhibitors, natural penicillin, and penicillinase resistance penicillin. Amongst these, the beta-lactamase inhibitors are anticipated to grow with a significant CAGR in the forecasted period. This is attributed towards the growing resistance to beta-lactam antibiotics. As the use of beta-lactam antibiotics increases, so does the emergence of antibiotic-resistant strains of bacteria. Beta-lactamase inhibitors can help overcome this resistance by inhibiting the activity of beta-lactamases, which are enzymes produced by some bacteria that break down beta-lactam antibiotics. Thus, owing to the above-mentioned factors the demand for beta-lactam antibiotics is anticipated to fuel the market growth in the forecasted period.
• Based on the route of administration, the market is segmented into oral, intravenous, and intramuscular. Amongst these, the oral route of administration is growing with a significant CAGR. This is attributed to the patient convenience and compliance factor. Many patients prefer the oral route of administration because it is less invasive and less intimidating than other routes of administration. Additionally, patient convenience is also fueling the market growth, penicillin can be taken orally, which makes it a convenient option for patients. Patients do not need to visit a healthcare provider for IV or IM administration, which can save time and reduce the risk of complications. These above-mentioned elements are anticipated to fuel the market growth for the penicillin market in the forecasted period.
• Based on the end-user, the market is segmented into hospitals, clinics and research institutes. Amongst these, the hospital segment is anticipated to grow with a significant CAGR in the forecasted period. penicillin is a commonly prescribed antibiotic for a wide range of infections. Additionally, hospitals are where a large no. of infections occurs and where antibiotics are often prescribed. Further, the hospital segment includes all sizes of hospitals, including small clinics and medical study centres. Thus, all these above-mentioned elements are anticipated to fuel the market growth of penicillin.
• For a better understanding of the market adoption of the Behavior Health industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is attributed to the rising prevalence of infectious diseases in this region. For instance, according to the Ministry of Health and family welfare 2022 report, around 22 crore people were diagnosed with tuberculosis in 2021, this account for 18% higher than in 2020. Thus, these above-mentioned elements are anticipated to boost market growth in the forecasted period.
• Some of the major players operating in the market include Pfizer Inc., Lupin., Bayer AG, Novartis Pharmaceutical Corporation, GSK plc., Merck & Co., Inc., Astellas Pharma Inc., Sanofi, Gilead lifesciences, Inc., FUJIFILM Toyama Chemical Co., Ltd.